The equity of plant-based protein company Beyond Meat continues its downward trajectory, with a significant 6.57% drop recorded on Monday. Market observers see no immediate relief in sight, as the primary driver for the latest sell-off was a quarterly revenue projection that fell substantially short of Wall Street’s expectations. This has prompted a wave of analyst downgrades and warnings of potential further declines.
Legal Scrutiny Adds to Operational Woes
Compounding the company’s challenges is emerging legal scrutiny. Several law firms, including Bleichmar Fonti & Auld LLP, are investigating potential securities law violations. The focus of these probes is an allegation that the company may have overstated the value of its long-lived assets prior to announcing a significant impairment charge. For investors, this introduces an additional layer of uncertainty, with potential regulatory repercussions or protracted litigation posing a threat to an already strained financial position.
Revenue Guidance Misses the Mark
The core of the current investor pessimism stems from a stark revision in outlook. For the fourth quarter, Beyond Meat now anticipates generating revenue in the range of only $60 million to $65 million. This forecast stands in sharp contrast to the consensus analyst estimate of $70.33 million. The shortfall, amounting to between $5 million and $10 million, highlights a fundamental issue: sustained weakness in consumer demand for plant-based meat alternatives. A sector once hailed as a high-growth market is increasingly being viewed as a niche segment with limited near-term potential.
Should investors sell immediately? Or is it worth buying Beyond Meat?
Wall Street Strategists Slash Price Targets
The investment community responded decisively to the disappointing update. Analysts at Mizuho Securities reduced their price target from $1.50 to $1.00 per share, maintaining an “Underperform” rating. Similarly, Barclays cut its target from $2.00 to $1.00, reiterating its “Underweight” stance on the stock.
Market experts cite intensified competition and a noted resurgence in demand for traditional animal protein in the U.S. market as key factors. A consistent pattern of declining performance across multiple consecutive quarters now points to a clear negative trend, with no visible catalyst for a reversal.
All attention is now fixed on the psychologically critical $1.00 share price level. Whether this threshold will hold or the downward momentum will persist is set to be determined in the coming trading sessions.
Ad
Beyond Meat Stock: Buy or Sell?! New Beyond Meat Analysis from December 9 delivers the answer:
The latest Beyond Meat figures speak for themselves: Urgent action needed for Beyond Meat investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 9.
Beyond Meat: Buy or sell? Read more here...
